A Podcast Series

The treatment landscape of metastatic castration-resistant prostate cancer (mCRPC) is continually evolving. In this podcast, an advanced practice provider and a medical oncologist discuss recent trials from the ASCO GU Symposium 2022 and how they plan to incorporate these data into clinical practice. Topics include the role of PARP inhibitors in the first-line setting for mCRPC and continuation of enzalutamide after progression. Listeners can earn 0.50 credit hours. Download the supplemental PowerPoint slides below for additional education.

If you have already listened to the podcast, use the button below to access the post-test and evaluation and receive your certificate.


Alicia Morgans, MD, MPH Genitourinary Medical Oncologist Medical Director, Survivorship Program Dana-Farber Cancer InstituteBoston, Massachusetts

Brenda Martone, MSN, ANP-BC, AOCNP Nurse Practitioner Genitourinary Oncology Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chicago, Illinois

Development Widget